← Browse by Condition
Medical Condition
burkitt lymphoma
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — burkitt lymphoma Clinical Trials
How many clinical trials are currently recruiting for burkitt lymphoma?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for burkitt lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for burkitt lymphoma?
burkitt lymphoma research spans Phase 1 (3 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a burkitt lymphoma clinical trial?
Eligibility criteria for burkitt lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05805605 Phase 2
Recruiting
Enrollment
56 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
NCT05794880
Recruiting
Enrollment
40 pts
Location
United States
Sponsor
Medical College of Wisconsin
NCT06060782 Phase 1
Recruiting
Enrollment
28 pts
Location
China
Sponsor
Fifth Affiliated Hospital, Sun...
NCT05544019 Phase 1
Recruiting
Enrollment
98 pts
Location
United States, Franc...
Sponsor
Schrödinger, Inc.
NCT06395103 Phase 1, Phase 2
Recruiting
Enrollment
90 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
Related Conditions
biphenotypic acute leukemia (2) follicular lymphoma (2) acute myelogenous leukemia (1) acute lymphocytic leukemia (1) undifferentiated leukemia (1) prolymphocytic leukemia (1) chronic myelogenous leukemia (1) plasma cell leukemia (1) myelodysplastic syndromes (1) leukemia myeloid (1) myelodysplastic syndrome with excess blasts 1 (1) relapsed t cell lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology